According to Bloomberg, the vaccine that Oxford University is working on with AstraZeneca Plc (AZN.UK) showed promising results in the initial phase of human testing. According to the researchers involved in the study, the vaccine was expected to increase the levels of antibodies and lymphocytes that fight the coronavirus. The results were published today in the medical journal The Lancet. While the above observations do not yet mean that the vaccine will be fully effective, it is a key step in the initial testing phase.
AstraZeneca Plc (AZN.UK) shares are highly volatile today. Successful reports on a potential vaccine inflame investors' hopes once again. Initially price soared by nearly 10%, however after a while the price started to decline and is approaching the support level at 90,510. In case of further downward movements, investors should focus on 81.310, where we have seen previous price reactions. It is worth bearing in mind that any reports related to the AstraZeneca vaccine may greatly affect the company's stock price. Source: xStation5
